Cliff Asness's PFE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 9.51 M shares of Pfizer Inc. (PFE) worth $230.99 M, representing 0.15% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2018, adding 8.7 M shares. Largest reduction occurred in Q1 2016, reducing 9.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +6.4 M | Add 0.00% | 6.4 M | $25.08 |
| Q2 2013 | +10.8 M | Add 0.00% | 10.8 M | $28.01 |
| Q3 2013 | -3.9 M | Reduce 36.13% | 6.9 M | $28.71 |
| Q4 2013 | +877,900 | Add 12.72% | 7.78 M | $30.63 |
| Q1 2014 | +1.67 M | Add 21.48% | 9.45 M | $32.12 |
| Q2 2014 | +946,856 | Add 10.02% | 10.4 M | $29.68 |
| Q3 2014 | +60,085 | Add 0.58% | 10.46 M | $29.57 |
| Q4 2014 | +3.48 M | Add 33.27% | 13.93 M | $31.15 |
| Q1 2015 | -995,563 | Reduce 7.15% | 12.94 M | $34.79 |
| Q2 2015 | +1.32 M | Add 10.23% | 14.26 M | $33.53 |
| Q3 2015 | +2.66 M | Add 18.62% | 16.92 M | $31.41 |
| Q4 2015 | +531,741 | Add 3.14% | 17.45 M | $32.28 |
| Q1 2016 | -9.36 M | Reduce 53.65% | 8.09 M | $29.64 |
| Q2 2016 | -181,134 | Reduce 2.24% | 7.91 M | $35.21 |
| Q3 2016 | +1.83 M | Add 23.19% | 9.74 M | $33.87 |
| Q4 2016 | +573,111 | Add 5.88% | 10.31 M | $32.48 |
| Q1 2017 | +559,289 | Add 5.42% | 10.87 M | $34.21 |
| Q2 2017 | +3.76 M | Add 34.58% | 14.63 M | $33.59 |
| Q3 2017 | +6.23 M | Add 42.56% | 20.86 M | $35.70 |
| Q4 2017 | -1.77 M | Reduce 8.48% | 19.09 M | $36.22 |
| Q1 2018 | -3.07 M | Reduce 16.07% | 16.02 M | $35.49 |
| Q2 2018 | -1.57 M | Reduce 9.81% | 14.45 M | $36.39 |
| Q3 2018 | +8.7 M | Add 60.21% | 23.15 M | $44.07 |
| Q4 2018 | +4.09 M | Add 17.68% | 27.24 M | $43.65 |
| Q1 2019 | -2.4 M | Reduce 8.81% | 24.84 M | $42.25 |
| Q2 2019 | -5.54 M | Reduce 22.31% | 19.3 M | $43.32 |
| Q3 2019 | -6.33 M | Reduce 32.79% | 12.97 M | $35.93 |
| Q4 2019 | +316,807 | Add 2.44% | 13.29 M | $38.88 |
| Q1 2020 | -2.22 M | Reduce 16.73% | 11.07 M | $32.64 |
| Q2 2020 | -1.12 M | Reduce 10.13% | 9.94 M | $32.70 |
| Q3 2020 | -2.04 M | Reduce 20.52% | 7.9 M | $36.70 |
| Q4 2020 | -3.61 M | Reduce 45.68% | 4.29 M | $36.44 |
| Q1 2021 | +1.03 M | Add 24.00% | 5.32 M | $36.07 |
| Q2 2021 | +78,542 | Add 1.48% | 5.4 M | $38.88 |
| Q3 2021 | +252,045 | Add 4.67% | 5.65 M | $43.01 |
| Q4 2021 | +1.19 M | Add 21.06% | 6.85 M | $59.05 |
| Q1 2022 | +3.86 M | Add 56.35% | 10.7 M | $51.77 |
| Q2 2022 | -138,739 | Reduce 1.30% | 10.56 M | $52.43 |
| Q3 2022 | +120,527 | Add 1.14% | 10.69 M | $43.76 |
| Q4 2022 | -845,459 | Reduce 7.91% | 9.84 M | $51.09 |
| Q1 2023 | -456,997 | Reduce 4.64% | 9.38 M | $40.53 |
| Q2 2023 | -3.98 M | Reduce 42.39% | 5.41 M | $36.28 |
| Q3 2023 | -262,490 | Reduce 4.86% | 5.14 M | $32.84 |
| Q4 2023 | -3.4 M | Reduce 66.17% | 1.74 M | $28.79 |
| Q1 2024 | -1.14 M | Reduce 65.34% | 602,994 | $27.75 |
| Q2 2024 | +9,435 | Add 1.56% | 612,429 | $27.87 |
| Q3 2024 | +1.06 M | Add 173.81% | 1.68 M | $28.94 |
| Q4 2024 | +5.02 M | Add 299.48% | 6.7 M | $26.53 |
| Q1 2025 | -622,115 | Reduce 9.29% | 6.08 M | $24.84 |
| Q2 2025 | -1.77 M | Reduce 29.19% | 4.3 M | $24.22 |
| Q3 2025 | +5.2 M | Add 120.92% | 9.51 M | $24.30 |
Cliff Asness's Pfizer Investment FAQs
Cliff Asness first purchased Pfizer Inc. (PFE) in Q4 2012, acquiring 6,398,129 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Pfizer Inc. (PFE) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 10,802,570 shares worth $302.58 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 9,505,615 shares of Pfizer Inc. (PFE), valued at approximately $230.99 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 0.15% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Pfizer Inc. (PFE) was 27,244,014 shares, as reported at the end of Q4 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.